A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
Michael J. Overman(The University of Texas MD Anderson Cancer Center), Harold M. Wright(Therapeutics Clinical Research), Hui Zou(Therapeutics Clinical Research), Lina Petrosyan(Therapeutics Clinical Research), Mariela Blum‐Murphy(The University of Texas MD Anderson Cancer Center), Jessica K Perer(Therapeutics Clinical Research), Cláudia Ramos(Therapeutics Clinical Research), Ming Wang(Wenzhou Medical University), Jack Li(FibroGen (United States)), Ramzi Melhem(Therapeutics Clinical Research)
Cited by 18
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846